Ovid Therapeutics Appoints Dr. Anna Greka, Harvard Medical School Professor, to Board of Directors
OVID has more than doubled off its 52-week low of $0.27.
Summary
Ovid Therapeutics has appointed Dr. Anna Greka, a distinguished professor from Harvard Medical School and a biotech veteran, to its Board of Directors, enhancing its scientific and strategic oversight.
Key Events · Executive and Board Changes · OVID
-
New Director Appointment
Dr. Anna Greka, M.D., Ph.D., a Professor of Medicine at Harvard Medical School and a leader at the Broad Institute, was appointed as a Class III director, effective June 15, 2026.
-
Enhanced Scientific Expertise
Dr. Greka brings extensive experience in kidney disease research, drug discovery, and biotech venture advising, strengthening the company's scientific and strategic guidance.
-
Committee Assignments
She will serve as a member of the Compensation Committee and the Science and Technology Committee of the Board.
-
Board Expansion
The Board of Directors will increase in size to seven directors with Dr. Greka's appointment.
Analysis · OVID · Life Sciences
The appointment of Dr. Anna Greka to Ovid Therapeutics' Board of Directors is a positive development, bringing significant scientific and industry expertise. Her background as a Harvard Medical School professor, Broad Institute leader, and biotech venture advisor strengthens the company's strategic and scientific guidance, particularly as it advances its pipeline. This move enhances corporate governance and signals a commitment to leveraging top-tier talent for future growth.
At the time of this filing, OVID was trading at $2.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $447.9M. The 52-week trading range was $0.27 to $3.11. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.